Mangalam Drugs And Organics Limited (MANGALAM) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Mangalam Drugs And Organics Limited ₹24.94, price ₹29.15, upside -14.4%, quality 31 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Mangalam Drugs And Organics Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹23.78 – ₹190.80 · fair‑value band ₹20.48 – ₹29.23 · the ₹29.15 price screens above the ₹24.94 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 27, 2026.
Follow Mangalam Drugs And Organics in your weekly email
Every Wednesday you see whether Mangalam Drugs And Organics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India.
Show more
Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers active pharmaceutical ingredients (API) products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, etodolac, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, olanzapine, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base; and tenofovir disoproxil base. In addition, the company offers specialty chemicals comprising l(+)menthol; 2,3-dihydrophthalazine-1, 4-dione or phthalazine-1,4-dione; and 4-cynoethyl-2-methy phenol. Further, it manufactures organic and inorganic chemicals, and heavy chemicals. Additionally, it offers active pharmaceutical ingredients; and products covering various therapeutic areas comprising anti-malaria, anti-retroviral, anti-hypertensive, anti-inflammatory, anti-convulsant, anti-viral, anti-rheumatic arthritis agents, and anti-bacterial, as well as develops product for anti-hypertensive indications. Mangalam Drugs & Organics Limited was incorporated in 1972 and is based in Mumbai, India.
Stock analysis
Mangalam Drugs And Organics Limited (MANGALAM) currently trades at ₹29.15, while our model-based Fair Value estimate is ₹24.94, 14.4% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ₹43.62 per share, and 2 of the 3 models we run sit above the ₹29.15 price.
Bear case: the Dividend Discount group reads lowest at ₹28.56, and 1 of the 3 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹20.48 (bear) to ₹29.23 (bull), the price of ₹29.15 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Mangalam Drugs And Organics Limited reported revenue of ₹2.3B in FY2026 versus ₹4.5B in FY2022, a compound −15.1%/yr. Reported net income was −₹444M in FY2026.
Key figures
Market cap ₹461M (≈ $4.8M) · P/S ratio 0.19 · EPS (TTM) ₹−28.05 · Dividend yield 9.2% · Net margin −19.1% · Return on equity −35.2% · Return on assets (EBIT) 1.9% · Operating margin −15.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 60% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −14%, MANGALAM screens cheaper than that median.
Fair Value models
Bear ₹20.48Fair Value ₹24.94Bull ₹29.23
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
11.7% (2021) → −14.3% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Compare Mangalam Drugs And Organics Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 585 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Mangalam Drugs And Organics Limited Fair Value". https://www.fairvalue-calculator.com/stock/MANGALAM
Frequently asked questions
Is Mangalam Drugs And Organics Limited (MANGALAM) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹24.94 versus a price of ₹29.15, about −14% upside (overvalued).
What is the fair value of MANGALAM?
Our model-based fair value for Mangalam Drugs And Organics Limited is ₹24.94 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹29.15.
What is the quality score of MANGALAM?
Mangalam Drugs And Organics Limited has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mangalam Drugs And Organics Limited (MANGALAM)?
Our model-based price target is the fair value of ₹24.94 (as of Sep 27, 2026) from 3 valuation models. Cautious scenario ₹20.48, optimistic scenario ₹29.23. It is a calculation from audited fundamentals, not an analyst target.
What is the Mangalam Drugs And Organics Limited stock forecast for 2026?
Our models put fair value at ₹24.94, about −14% upside versus a price of ₹29.15 (overvalued). Cautious scenario ₹20.48, optimistic scenario ₹29.23. The calculation is refreshed regularly with new filings.
What is the revenue of Mangalam Drugs And Organics Limited (MANGALAM)?
Mangalam Drugs And Organics Limited reported trailing-twelve-month revenue of about ₹2.3B (latest available figure, as of Sep 27, 2026).
Does Mangalam Drugs And Organics Limited pay a dividend?
Mangalam Drugs And Organics Limited currently shows a dividend yield of about 9.22% relative to its recent price (as of Sep 27, 2026).
What is the intrinsic value of Mangalam Drugs And Organics Limited (MANGALAM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mangalam Drugs And Organics Limited it is ₹24.94 per share (as of Sep 27, 2026), against a price of ₹29.15. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Mangalam Drugs And Organics Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, MANGALAM trades above its calculated fair value: price ₹29.15, fair value ₹24.94, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MANGALAM?
No. The price is what the market pays today (₹29.15); the fair value is what the company's own numbers justify (₹24.94). For Mangalam Drugs And Organics Limited the two are ₹4.21 per share apart. That gap is exactly why we show both numbers side by side.
How much is Mangalam Drugs And Organics Limited worth?
The market values Mangalam Drugs And Organics Limited at about ₹461M (market capitalisation, as of Sep 27, 2026). Per share that is ₹29.15; our models calculate a fair value of ₹24.94 per share.
What do the bullish and bearish scenarios say about MANGALAM?
Our models span a range for Mangalam Drugs And Organics Limited: cautious scenario ₹20.48, base ₹24.94, optimistic ₹29.23 per share (as of Sep 27, 2026, price ₹29.15). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Mangalam Drugs And Organics Limited (MANGALAM)?
Balance-sheet figures for Mangalam Drugs And Organics Limited (as of Sep 27, 2026): return on equity −35.2%, debt of 0.07 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is MANGALAM from its 52-week high?
Mangalam Drugs And Organics Limited trades at ₹29.15, about 60% below its 52-week high of ₹72.67 and 23% above the low of ₹23.78 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹24.94 is for.
Which stocks are comparable to Mangalam Drugs And Organics Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mangalam Drugs And Organics Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹29.15, calculated fair value ₹24.94 (−14%), Quality Score 31/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MANGALAM calculated?
We run Mangalam Drugs And Organics Limited through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹24.94, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Mangalam Drugs And Organics Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mangalam Drugs And Organics Limited (MANGALAM)?
The closing price on Oct 1, 2026 was ₹29.15. Our model-based fair value is ₹24.94, about −14% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mangalam Drugs And Organics Limited right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Mangalam Drugs And Organics Limited
How large is the market capitalisation of Mangalam Drugs And Organics Limited (MANGALAM)?
The market capitalisation of Mangalam Drugs And Organics Limited is ₹461M (≈ $4.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mangalam Drugs And Organics Limited (MANGALAM)?
The price-to-sales ratio of Mangalam Drugs And Organics Limited is 0.19 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Mangalam Drugs And Organics Limited (MANGALAM)?
Earnings per share at Mangalam Drugs And Organics Limited are ₹−28.05. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Mangalam Drugs And Organics Limited (MANGALAM)?
The dividend yield of Mangalam Drugs And Organics Limited is 9.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Mangalam Drugs And Organics Limited (MANGALAM)?
The net margin of Mangalam Drugs And Organics Limited is −19.1% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Mangalam Drugs And Organics Limited (MANGALAM)?
The return on equity (ROE) of Mangalam Drugs And Organics Limited is −35.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mangalam Drugs And Organics Limited (MANGALAM)?
On an EBIT basis the return on assets of Mangalam Drugs And Organics Limited is 1.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mangalam Drugs And Organics Limited (MANGALAM)?
The operating margin of Mangalam Drugs And Organics Limited is −15.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mangalam Drugs And Organics Limited (MANGALAM)?
Revenue at Mangalam Drugs And Organics Limited is growing −7.5% versus a year earlier (3y avg −14.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Mangalam Drugs And Organics Limited (MANGALAM)?
Earnings per share at Mangalam Drugs And Organics Limited are growing −98.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Mangalam Drugs And Organics Limited (MANGALAM) generate?
The free cash flow of Mangalam Drugs And Organics Limited is −₹208M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Mangalam Drugs And Organics Limited (MANGALAM) carry?
The net debt of Mangalam Drugs And Organics Limited is ₹1.0B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Mangalam Drugs And Organics Limited in the live analysis
One click puts Mangalam Drugs And Organics Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
